山东大学耳鼻喉眼学报 ›› 2021, Vol. 35 ›› Issue (1): 114-118.doi: 10.6040/j.issn.1673-3770.0.2020.146

• • 上一篇    下一篇

IL-36在慢性鼻-鼻窦炎伴鼻息肉中的研究进展

慕婷婷1,2,杨玉娟1综述张宇1,宋西成1,2审校   

  1. 1. 青岛大学附属烟台毓璜顶医院 耳鼻咽喉头颈外科, 山东 烟台 264000;
    2. 滨州医学院, 山东 烟台 264003
  • 发布日期:2021-02-01
  • 通讯作者: 宋西成. E-mail:songxicheng@126.com
  • 基金资助:
    国家自然科学基金(81670907)

Research progress of IL-36 in chronic rhinosinusitis with nasal polyps

MU Tingting1,2, YANG Yujuan1Overview   

  1. ZHANG Yu1, SONG Xicheng1, 2Guidance1. Department of Otorhinolaryngology & Head and Neck Surgery, The Affiliated Yantai Yuhuangding Hospital, Yantai 264000, Shandong, China;
    2. Binzhou Medical College, Yantai 264003, Shandong, China
  • Published:2021-02-01

摘要: 白介素-36(IL-36)是IL-1超家族成员(IL-1F)之一,在上皮细胞和特异性免疫细胞中具有生物活性,主要功能包括促进细胞的活化、分泌细胞因子和趋化因子、招募和激活不同的免疫细胞等。近年有学者研究发现,IL-36家族在慢性鼻-鼻窦炎伴鼻息肉(CRSwNP)发病中具有一定的作用。就IL-36的生物学特征及其在慢性鼻-鼻窦炎伴鼻息肉中促进炎症反应、组织重塑、破坏上皮屏障等方面的研究进展进行综述。

关键词: IL-36, CRSwNP, 免疫应答, 组织重塑, 上皮屏障

Abstract: Interleukin-36(IL-36), a member of the IL-1 superfamily(IL-1F), is biologically active in epithelial cells and in specific immune cells. Its main functions include promoting cell activation, secreting cytokines and chemokines, and recruiting and activating different immune cells. Recent studies have found that the IL-36 family has a role in the pathogenesis of chronic rhinosinusitis with nasal polyps(CRSwNP). This article reviews the research progress and biological characteristics of IL-36 in promoting the inflammatory response, tissue remodeling, and disrupting the epithelial barrier in chronic rhinosinusitis with nasal polyps.

Key words: IL-36, CRSwNP, Immune response, Tissue Inhibitor of Metalloproteinases, Epithelial barrier

中图分类号: 

  • 765.4
[1] Dietrich D, Martin P, Flacher V, et al. Interleukin-36 potently stimulates human M2 macrophages, Langerhans cells and keratinocytes to produce pro-inflammatory cytokines[J]. Cytokine, 2016, 84: 88-98. doi:10.1016/j.cyto.2016.05.012.
[2] Yuan ZC, Xu WD, Liu XY, et al. Biology of IL-36 signaling and its role in systemic inflammatory diseases[J]. Front Immunol, 2019, 10: 2532. doi:10.3389/fimmu.2019.02532.
[3] Hashiguchi Y, Yabe R, Chung SH, et al. IL-36α from skin-resident cells plays an important role in the pathogenesis of imiquimod-induced psoriasiform dermatitis by forming a local autoamplification loop[J]. J Immunol, 2018, 201(1): 167-182. doi:10.4049/jimmunol.1701157.
[4] Bassoy EY, Towne JE, Gabay C. Regulation and function of interleukin-36 cytokines[J]. Immunol Rev, 2018, 281(1): 169-178. doi:10.1111/imr.12610.
[5] Zhou L, Todorovic V. Interleukin-36: structure, signaling and function[M] //Advances in Experimental Medicine and Biology. New York, NY: Springer US, 2020. doi:10.1007/5584_2020_488
[6] van de Veerdonk FL, Netea MG. New insights in the immunobiology of IL-1 family members[J]. Front Immunol, 2013, 4: 167. doi:10.3389/fimmu.2013.00167.
[7] Walsh PT, Fallon PG. The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases[J]. Ann N Y Acad Sci, 2018, 1417(1): 23-34. doi:10.1111/nyas.13280.
[8] van de Veerdonk FL, de Graaf DM, Joosten LA, et al. Biology of IL-38 and its role in disease[J]. Immunol Rev, 2018, 281(1): 191-196. doi:10.1111/imr.12612.
[9] Gabay C, Towne JE. Regulation and function of interleukin-36 cytokines in homeostasis and pathological conditions[J]. J Leukoc Biol, 2015, 97(4): 645-652. doi:10.1189/jlb.3RI1014-495R.
[10] Walsh PT, Fallon PG. The emergence of the IL-36 cytokine family as novel targets for inflammatory diseases[J]. Ann N Y Acad Sci, 2018, 1417(1): 23-34. doi:10.1111/nyas.13280.
[11] Foster AM, Baliwag J, Chen CS, et al. IL-36 promotes myeloid cell infiltration, activation, and inflammatory activity in skin[J]. J Immunol, 2014, 192(12): 6053-6061. doi:10.4049/jimmunol.1301481.
[12] Henry CM, Sullivan GP, Clancy DM, et al. Neutrophil-derived proteases escalate inflammation through activation of IL-36 family cytokines[J]. Cell Rep, 2016, 14(4): 708-722. doi:10.1016/j.celrep.2015.12.072.
[13] Murrieta-Coxca JM, Rodríguez-Martínez S, Cancino-Diaz ME, et al. IL-36 cytokines: regulators of inflammatory responses and their emerging role in immunology of reproduction[J]. Int J Mol Sci, 2019, 20(7): E1649. doi:10.3390/ijms20071649.
[14] Buhl AL, Wenzel J. Interleukin-36 in infectious and inflammatory skin diseases[J]. Front Immunol, 2019, 10: 1162. doi:10.3389/fimmu.2019.01162.
[15] Vigne S, Palmer G, Martin P, et al. IL-36 signaling amplifies Th1 responses by enhancing proliferation and Th1 polarization of naive CD4+T cells[J]. Blood, 2012, 120(17): 3478-3487. doi:10.1182/blood-2012-06-439026.
[16] Ge Y, Huang M, Yao YM. Recent advances in the biology of IL-1 family cytokines and their potential roles in development of Sepsis[J]. Cytokine Growth Factor Rev, 2019, 45: 24-34. doi:10.1016/j.cytogfr.2018.12.004.
[17] Ding LP, Wang XH, Hong XP, et al. IL-36 cytokines in autoimmunity and inflammatory disease[J]. Oncotarget, 2018, 9(2): 2895-2901. doi:10.18632/oncotarget.22814.
[18] Sato Y, Fujimura T, Kambayashi Y, et al. Recurrent multiple squamous cell carcinomas on the scalp in a patient with juvenile dermatomyositis[J]. Case Rep Oncol, 2017, 10(1): 106-111. doi:10.1159/000456001.
[19] Weinstein AM, Giraldo NA, Petitprez F, et al. Association of IL-36γ with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer[J]. Cancer Immunol Immunother, 2019, 68(1): 109-120. doi:10.1007/s00262-018-2259-0.
[20] Turtoi A, Brown I, Schl?ger M, et al. Gene expression profile of human lymphocytes exposed to(211)At alpha particles[J]. Radiat Res, 2010, 174(2): 125-136. doi:10.1667/RR1659.1.
[21] Jiang ZW, Liu YQ, Li CW, et al. IL-36γ induced by the TLR3-SLUG-VDR Axis promotes wound healing via REG3A[J]. J Invest Dermatol, 2017, 137(12): 2620-2629. doi:10.1016/j.jid.2017.07.820.
[22] Medina-Contreras O, Harusato A, Nishio H, et al. Cutting edge: IL-36 receptor promotes resolution of intestinal damage[J]. J Immunol, 2016, 196(1): 34-38. doi:10.4049/jimmunol.1501312.
[23] Fokkens WJ, Lund VJ, Hopkins C, et al. European position paper on rhinosinusitis and nasal polyps 2020[J]. Rhinology, 2020, 58(Suppl S29): 1-464. doi:10.4193/Rhin20.600.
[24] Orlandi RR, Kingdom TT, Hwang PH, et al. International consensus statement on allergy and rhinology: rhinosinusitis[J]. Int Forum Allergy Rhinol, 2016, 6(Suppl 1): S22-S209. doi:10.1002/alr.21695.
[25] Chaaban MR, Kejner A, Rowe SM, et al. Cystic fibrosis chronic rhinosinusitis: a comprehensive review[J]. Am J Rhinol Allergy, 2013, 27(5): 387-395. doi:10.2500/ajra.2013.27.3919.
[26] Joo YH, Kim HK, Hak Choi I, et al. Increased expression of interleukin 36 in chronic rhinosinusitis and its contribution to chemokine secretion and increased epithelial permeability[J]. Cytokine, 2020, 125: 154798. doi:10.1016/j.cyto.2019.154798.
[27] Wang CS, Yan B, Zhang L. The epithelium-derived inflammatory mediators of chronic rhinosinusitis with nasal polyps[J]. Expert Rev Clin Immunol, 2020, 16(3): 293-310. doi:10.1080/1744666X.2020.1723417.
[28] 李华斌, 赖玉婷. 慢性鼻-鼻窦炎的发病机制及诊疗进展[J]. 山东大学耳鼻喉眼学报, 2018, 32(3): 4-9. LI Huabin, LAI Yuting. Pathogenesis, diagnosis, and treatment of chronic rhinosinusitis[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2018, 32(3): 4-9.
[29] Wang H, Li ZY, Jiang WX, et al. The activation and function of IL-36γ in neutrophilic inflammation in chronic rhinosinusitis[J]. J Allergy Clin Immunol, 2018, 141(5): 1646-1658. doi:10.1016/j.jaci.2017.12.972.
[30] Aoyagi T, Newstead MW, Zeng X, et al. IL-36 receptor deletion attenuates lung injury and decreases mortality in murine influenza pneumonia[J]. Mucosal Immunol, 2017, 10(4): 1043-1055. doi:10.1038/mi.2016.107.
[31] Agache I, Akdis CA. Endotypes of allergic diseases and asthma: an important step in building blocks for the future of precision medicine[J]. Allergol Int, 2016, 65(3): 243-252. doi:10.1016/j.alit.2016.04.011.
[32] 张宇, 宋西成. 慢性鼻窦炎伴鼻息肉与哮喘的相关性机制及治疗策略研究进展[J]. 山东大学耳鼻喉眼学报, 2019, 33(1): 49-52. ZHANG Yu, SONG Xicheng. Advances in interaction mechanisms and treatment strategy between chronic rhinosinusitis with nasal polyp and asthma[J]. Journal of Otolaryngology and Ophthalmology of Shandong University, 2019, 33(1): 49-52.
[33] Bridgewood C, Stacey M, Alase A, et al. IL-36γ has proinflammatory effects on human endothelial cells[J]. Exp Dermatol, 2017, 26(5): 402-408. doi:10.1111/exd.13228.
[34] Muller WA. Transendothelial migration: unifying principles from the endothelial perspective[J]. Immunol Rev, 2016, 273(1): 61-75. doi:10.1111/imr.12443.
[35] Heath JE, Scholz GM, Veith PD, et al. IL-36γ regulates mediators of tissue homeostasis in epithelial cells[J]. Cytokine, 2019, 119: 24-31. doi:10.1016/j.cyto.2019.02.012.
[36] 纪文君, 赵春源. 组织重塑与慢性鼻-鼻窦炎发病机制的相关性[J]. 中国耳鼻咽喉颅底外科杂志, 2014, 20(1): 85-88, 92. doi:10.11798/j.issn.1007-1520.201401027
[37] Wynne M, Atkinson C, Schlosser RJ, et al. Contribution of epithelial cell dysfunction to the pathogenesis of chronic rhinosinusitis with nasal polyps[J]. Am J Rhinol Allergy, 2019, 33(6): 782-790. doi:10.1177/1945892419868588.
[38] Jiao J, Wang CS, Zhang L. Epithelial physical barrier defects in chronic rhinosinusitis[J]. Expert Rev Clin Immunol, 2019, 15(6): 679-688. doi:10.1080/1744666X.2019.1601556.
[39] Soyka MB, Wawrzyniak P, Eiwegger T, et al. Defective epithelial barrier in chronic rhinosinusitis: the regulation of tight junctions by IFN-γ and IL-4[J]. J Allergy Clin Immunol, 2012, 130(5): 1087-1096.e10. doi:10.1016/j.jaci.2012.05.052.
[1] 王文晴,张丹,朱梦迪,王路阳,杨培培,孙思思,张秋敏,周慧. 慢性鼻窦炎伴鼻息肉复发手术时临床及组织病理学特征变化[J]. 山东大学耳鼻喉眼学报, 2025, 39(1): 46-53.
[2] 张诗涵,刘红兵. 基质金属蛋白酶对慢性鼻窦炎组织重塑的影响[J]. 山东大学耳鼻喉眼学报, 2024, 38(3): 116-123.
[3] 王明明,罗洋,贺少娟,张现兴,李学忠. 慢性鼻窦炎鼻息肉基底干细胞转录组生物信息学分析[J]. 山东大学耳鼻喉眼学报, 2023, 37(5): 6-15.
[4] 黄丹怡,张婷,陈静,张薇. 上皮屏障在慢性鼻窦炎伴鼻息肉中的研究进展[J]. 山东大学耳鼻喉眼学报, 2022, 36(3): 78-83.
[5] 李春花,刘肖,刘红兵. 半乳糖凝集素10与慢性鼻窦炎伴鼻息肉[J]. 山东大学耳鼻喉眼学报, 2021, 35(3): 106-111.
[6] 刘娜,闫娟,刘涛. 慢性鼻-鼻窦炎的免疫机制研究进展[J]. 山东大学耳鼻喉眼学报, 2014, 28(3): 86-88.
[7] 李雪盛,钱进,李厚恩,李进让. 慢性鼻-鼻窦炎的组织重塑研究进展[J]. 山东大学耳鼻喉眼学报, 2014, 28(1): 84-86.
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!